EX-10.1
from 8-K
12 pages
Intermune, Inc. Amended and Restated 2000 Equity Incentive Plan Adopted January 31, 2000 Approved by Stockholders: March 20, 2000 Amended On: April 4, 2002 and June 19, 2002 Approved by Stockholders: June 19, 2002 Amended and Restated On: April 2, 2004 Approved by Stockholders: May 27, 2004 Amended and Restated On: March 7, 2007 Amended On: April 27, 2007 Approved by Stockholders: May 15, 2007 Amended and Approved by Stockholders: May 21, 2009 Amended and Approved by Stockholders: May 10, 2011 Amended and Restated and Approved by Stockholders: June 4, 2012 Amended and Restated and Approved by Stockholders: May 30, 2013
12/34/56
EX-10.1
from 8-K
17 pages
Intermune, Inc. Amended and Restated 2000 Equity Incentive Plan Adopted January 31, 2000 Approved by Stockholders: March 20, 2000 Amended On: April 4, 2002 and June 19, 2002 Approved by Stockholders: June 19, 2002 Amended and Restated On: April 2, 2004 Approved by Stockholders: May 27, 2004 Amended and Restated On: March 7, 2007 Amended On: April 27, 2007 Approved by Stockholders: May 15, 2007 Amended and Approved by Stockholders: May 21, 2009 Amended and Approved by Stockholders: May 10, 2011 Amended and Restated and Approved by Stockholders: June 4, 2012
12/34/56
EX-10.1
from 10-Q
16 pages
Intermune, Inc. Amended and Restated 2000 Equity Incentive Plan Adopted January 31, 2000 Approved by Stockholders: March 20, 2000 Amended On: April 4, 2002 and June 19, 2002 Approved by Stockholders: June 19, 2002 Amended and Restated On: April 2, 2004 Approved by Stockholders: May 27, 2004 Amended and Restated On: March 7, 2007 Amended On: April 27, 2007 Approved by Stockholders: May 15, 2007 Amended and Approved by Stockholders: May 21, 2009 Amended and Approved by Stockholders: May 10, 2011
12/34/56
EX-10.47A
from 10-K
2 pages
May 23, 2003 Scott D. Seiwert, PH.D. 114 Longs Pk. Dr. Lyons, Co 80540 Dear Scott: On Behalf of Intermune, Inc. (The “Company”), We Are Pleased to Offer You the Position of Senior Director, Applied Biochemistry, Pharmacogenomics and Proteomics, Reporting to Vice President of Biopharmacology Research, Larry Blatt, PH.D. the Terms of Your Employment Will Be as Follows
12/34/56